Reviewing the latest research on value-based care, clinical pathways, and precision medicine
Patient-provider discussions about treatment costs is associated with lower out-of-pocket costs while maintaining the quality cancer care, according to a recent study.
Study findings show 5% of men diagnosed with prostate cancer accounted for 26% of the total cost of care for all men diagnosed in 2009.
Study results suggest the budget impact of adopting avapritinib as a treatment option for metastatic or unresectable GIST is minimal.
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma.
Application of ASCO value framework to compare the efficacy of treatment options for HCC found higher scores among FDA-approved therapies than those that were not.
Older patients with MCL have a high rate of comorbidities impacting treatment choices and OS.